A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

CareVax Vaccine Tracking Program Launches

CareVax Vaccine tracking program designed to support the millions of individuals that will receive the COVID-19 vaccine has been launched by Care Angel.

CareVax patients will be given access to vaccine and COVID-19 education through ANGEL, a digital workforce of virtual nurse assistants that gathers clinical and non-clinical information, and when necessary, automatically triages users to the appropriate healthcare resources to address post-inoculation care needs. Powered by the company’s SmartCare Ecosystem Platform, ANGEL has the ability to augment the capacity of already exhausted clinical resources by 100X+ or more in order to manage and monitor for COVID-19 and vaccination symptoms for populations at scale, using omni-channels such as phone, text and chat.

“Before the pandemic, there had been already a massive global shortage of nurses, providers and family caregivers. This unprecedented global health crisis has exacerbated these human resources beyond capacity and caused an unnecessary caregiving burden leading to unrelenting suffering, deaths, long-term health and mental health issues, not to mention tremendous isolation for the aging, the sick and neediest populations,” said Lena Nikolnikov, Vice President of Product & Clinical Solutions at Care Angel.

CareVax is being released in the US first, internationally in early Q1, and is poised to work with government public health agencies at the federal, state, local county, and city levels offering a data-driven solution that can provide real-time analytic, surveillance and market intelligence in order to make more informed care decisions.

The program can be deployed stand alone or along with Care Angel’s HEALS COVID engagement and tracking offerings for employers and schools intended to help track and monitor at-risk populations, including exposure to COVID-19 positive cases and the need to quarantine. The initiative empowers vulnerable individuals with personalized health management, monitoring, education, contact tracing and triage to testing as well as care navigation.

Demand for scalable, quickly deployable solutions to manage large populations has accelerated due to the combination of the COVID-19 pandemic, vaccination distribution and the shortage of providers and care teams, domestically and across the world.

“After millions of calls and texts tracking COVID-19 in 2020, we see 2021 as a pivotal year for Care Angel to help globally as the critical need for resources that can deliver meaningful healthcare conversations at scale has been thrust into the global spotlight,” said Wolf Shlagman, CEO of Care Angel. “Sitting squarely at the intersection of digital health, telemedicine, AI and COVID-19, working with some of the largest health organizations on the planet, we are proud to already be having a noticeable impact on public health and the health and safety of society’s most vulnerable populations.”

Care Angel partners with large health plans, providers, health systems, pharma and government agencies to tackle some of the most challenging and costly elements of healthcare, namely, care management, health monitoring and reporting for vulnerable and at-risk populations.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy